Gland Pharma Share Price Target 2026 Analyst Forecast Bull and Bear Case

Gland Pharma (NSE: GLAND) is a Injectable Pharmaceuticals and B2B Generics company trading at Rs 2,202 with a market capitalisation of Rs 35,872 crore. Analysts have set the Gland Pharma share price target at Rs 2,650 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Gland Pharma Share Price Target 2026: Key Takeaways

• Gland Pharma share price target 2026: Rs 2,650 (20% upside from CMP Rs 2,202)
• Bull case: Rs 3,200 | Bear case: Rs 1,750
• Ticker: GLAND | Sector: Injectable Pharmaceuticals and B2B Generics | MCap: Rs 35,872 crore
• 52W range: Rs 1,526 to Rs 3,612 | PE: 22x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Gland Pharma Company Overview

Gland Pharma (NSE: GLAND) is a Hyderabad-based China Fosun-subsidiary pharmaceutical company and India’s largest B2B injectable company supplying complex injectables, sterile APIs, and oncology products to regulated US, EU, and international markets, with FY26 US injectable approvals resuming growth. At CMP Rs 2,202 against a 52 week range of Rs 1,526 to Rs 3,612, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 35,872 crore with trailing PE of 22x. Compared to peers in injectables like Piramal Pharma and Strides Pharma, Gland Pharma is positioned as a potential re-rating candidate toward the Rs 2,650 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	GLAND
Sector	Injectable Pharmaceuticals and B2B Generics
CMP (2026)	Rs 2,202
52 Week High	Rs 3,612
52 Week Low	Rs 1,526
Market Cap	Rs 35,872 crore
Trailing PE	22x
12-Month Analyst Target	Rs 2,650
Bull Case Target	Rs 3,200
Bear Case Target	Rs 1,750

Why Is the Gland Pharma Share Price Target Set at Rs 2,650 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Gland Pharma share price target of Rs 2,650 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating. The Rs 2,650 price objective represents the base case with FY27 execution as the key variable.

Structural Sector Tailwinds in Injectable Pharmaceuticals and B2B Generics

The Injectable Pharmaceuticals and B2B Generics sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Gland Pharma’s position among peers in injectables like Piramal Pharma and Strides Pharma creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 3,200 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Gland Pharma’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 2,650 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Gland Pharma’s Injectable Pharmaceuticals and B2B Generics operations, improving the probability of achieving the Rs 2,650 price objective through FY27 earnings delivery.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 22x PE, Gland Pharma is positioned as a beneficiary of institutional reallocation, providing a tailwind toward the Rs 3,200 bull case over the medium term.

Gland Pharma Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Gland Pharma Share Price Target

Near-term support for Gland Pharma is anchored close to the 52 week low of Rs 1,526. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors can use the 52 week low as an entry reference while awaiting FY27 earnings confirmation.

12-Month Gland Pharma Share Price Target 2026

The 12-month Gland Pharma share price target 2026 is Rs 2,650, implying approximately 20 percent upside from CMP Rs 2,202. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Track live on NSE ticker GLAND.

Long Term Gland Pharma Share Price Target: FY27 to FY28

The long term Gland Pharma share price target for FY27 to FY28 is Rs 3,200 in the bull case, requiring full earnings delivery, re-rating among peers in injectables like Piramal Pharma and Strides Pharma, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Gland Pharma in 2026

Bull Case Gland Pharma Share Price Target: Rs 3,200

The bull case Gland Pharma share price target of Rs 3,200 materialises when FY27 earnings beat analyst estimates, Injectable Pharmaceuticals and B2B Generics tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 2,202, this represents approximately 45 percent potential upside.

Bear Case Gland Pharma Share Price Target: Rs 1,750

The bear case Gland Pharma share price target of Rs 1,750 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 1,526.

Scenario	Target	Key Conditions
Bull Case	Rs 3,200	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 2,650	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 1,750	FY27 miss, guidance cut, FII outflows persist

Key Risks That Could Derail the Gland Pharma 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Gland Pharma share price target of Rs 2,650, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples. This is the most direct company-specific risk to the Rs 2,650 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among Injectable Pharmaceuticals and B2B Generics Peers

Intensifying competition from peers in injectables like Piramal Pharma and Strides Pharma could compress Gland Pharma’s market share and pricing power. This structural risk must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 2,650 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.

How to Invest in Gland Pharma

Check the Univest Screener for live data

Before considering any investment based on the Gland Pharma share price target of Rs 2,650, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Injectable Pharmaceuticals and B2B Generics sector demand.

Open a Demat account with a SEBI registered stockbroker to trade Gland Pharma (NSE: GLAND) with regulatory protection. Study the competitive landscape among peers in injectables like Piramal Pharma and Strides Pharma before executing any position.

Plan your entry using the 52 week low of Rs 1,526 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 2,650 price objective. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Gland Pharma’s live share price and receive daily stock recommendations.

FAQs on Gland Pharma Share Price Target 2026

What is the Gland Pharma share price target for 2026?

Ans. The Gland Pharma share price target 2026 is Rs 2,650, implying approximately 20 percent upside from CMP Rs 2,202. Bull case is Rs 3,200, bear case is Rs 1,750.

What was the Gland Pharma share price target for 2025?

Ans. The 2025 price objective for Gland Pharma was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 2,650, reflecting FY27 growth potential from CMP Rs 2,202.

Is Gland Pharma a good investment at Rs 2,202?

Ans. At Rs 2,202, Gland Pharma offers potential upside toward Rs 2,650 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance and portfolio goals. Consult a SEBI registered financial advisor before investing.

What are the key risks to the Gland Pharma share price target 2026?

Ans. Key risks to the Gland Pharma share price target of Rs 2,650 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Injectable Pharmaceuticals and B2B Generics. Monitoring quarterly results is essential.

What is the 52 week high and low of Gland Pharma?

Ans. The 52 week high of Gland Pharma is Rs 3,612 and the 52 week low is Rs 1,526. At CMP Rs 2,202, the stock is below its 52 week high and offers potential upside toward the Rs 2,650 price objective.

What are the main growth catalysts for Gland Pharma in 2026?

Ans. Key catalysts include FY27 PAT recovery, Injectable Pharmaceuticals and B2B Generics sector tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Gland Pharma compare to its peers?

Ans. Gland Pharma operates in Injectable Pharmaceuticals and B2B Generics alongside peers in injectables like Piramal Pharma and Strides Pharma. At CMP Rs 2,202 with MCap Rs 35,872 crore, it is a potential re-rating candidate toward the Gland Pharma share price target of Rs 2,650 on FY27 delivery.

What is the Gland Pharma share price target for 2027?

Ans. The long-term Gland Pharma share price target for FY27 to FY28 is Rs 3,200 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.